{"id":18117,"date":"2017-12-21T11:22:58","date_gmt":"2017-12-21T11:22:58","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=18117"},"modified":"2018-11-13T07:28:08","modified_gmt":"2018-11-13T07:28:08","slug":"the-emerging-roles-of-trpv4-in-cancer","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol10no4\/the-emerging-roles-of-trpv4-in-cancer\/","title":{"rendered":"The Emerging Roles of TRPV4 in Cancer"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

The transient receptor potential (TRP) ion channel family constitutes a diverse group of mostly non-selective cation channels that are further divided into seven subfamilies, namely TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), TRPA (ankyrin) and TRPN (this subfamily is not found in mammals).1,2<\/sup> TRP ion channels exhibit differences in ion selectivity, modes of activation and physiological functions.2<\/sup> The TRPV subfamily consists of six distinct members, denoted as TRPV1-6.2<\/sup> TRPV4 is a member of the TRPV ion channel family which is permeable to both Ca2+ <\/sup>and Na+ <\/sup>(3). TRPV4 has been implicated in various physiological processes such as osmoregulation, thermoregulation, and mechanosensation, to name a few.2,4,5<\/sup> The mechanism of activation of TRPV4 is found to be polymodal, since it is responsive to multiple stimuli including heat, cell swelling, phorbol esters and arachidonic acid.2,4-8<\/sup><\/p>\n

The involvement of TRP channels in carcinogenesis is increasingly recognised, as evidenced by the growing number of studies assessing the consequences of aberrant expression of TRP ion channels in different aspects of cancer progression such as proliferation, apoptosis, angiogenesis, migration, invasion and metastasis.9-14<\/sup> Among the TRPV ion channels, TRPV4 has recently captured a great attention in the fields of calcium signalling and cancer.<\/p>\n

Thus, we aim to highlight the reported roles of TRPV4 and its involvement in cancer hallmarks: i) self-sufficiency in growth signals, ii) insensitivity to growth-inhibitory signals, iii) resistance towards apoptosis, iv) infinite ability to replicate, v) sustained angiogenesis (induction of new blood vessels), and vi) tissue invasion and metastasis.15,16<\/sup><\/p>\n

TRPV4 and Cancer<\/strong><\/p>\n

As a group, TRPV channels have been implicated in the regulation of cancer-related processes such as proliferation, apoptosis, angiogenesis, migration and invasion.17<\/sup> Despite the well-documented roles of other TRPV channels (such as TRPV6) in various types of cancer,9,10,18-21<\/sup> studies assessing the involvement of TRPV4 in cancer remain limited.<\/p>\n

TRPV4 and Cell Proliferation<\/strong><\/p>\n

Evidence from previous studies supports a role for TRPV4 in regulating cell proliferation in several cell types including human brain capillary endothelial cells22<\/sup> and esophageal epithelial cells.23<\/sup> In the context of cancer, Thoppil and his colleagues24<\/sup> showed that reduced expression of the mechanosensitive ion channel TRPV4 in tumour endothelial cells (TEC) causes an increase in proliferation which may contribute to abnormal tumour angiogenesis. In addition, pharmacological activation of TRPV4 with a selective TRPV4 activator GSK1016790A showed decreased TEC proliferation in vitro<\/em>. Compared to TEC proliferation, GSK1016790A-activated TRPV4 displayed no effect on the proliferation of normal endothelial cells. The reduced TEC proliferation by TRPV4 activation was correlated with a decrease in high basal ERK1\/2 phosphorylation.24<\/sup> The authors proposed that TRPV4 channels are able to regulate tumour angiogenesis by selectively inhibiting TEC proliferation via modulation of the ERK pathway.24<\/sup><\/p>\n

Recent evidence from independent studies by Lee and co-researchers25<\/sup> found that TRPV4 is dispensable for breast cancer cell proliferation since there was no effect on the proliferation of 4T07 breast cancer metastasis model cell line (which highly expressed TRPV4) compared to control cells when TRPV4 was silenced in this study model. This finding is also consistent with the results obtained by Peters et al<\/em>26<\/sup> where pharmacological inhibition of TRPV4 using RN 1734 (1-10 \u00b5M) is not anti-proliferative in both MDA-MB-231 (moderate levels of TRPV4) and MDA-MB-468 (high levels of TRPV4) basal-like breast cancer cell lines.<\/p>\n

In the case of colorectal cancer, recent studies suggest that TRPV4 may be involved in colorectal cancer cell proliferation.27<\/sup> Using MTT cell proliferation assay, Wasilewski et al<\/em>27<\/sup> observed that co-incubation of fatty acid amide hydrolase inhibitor PF-3845 with the non-classical cannabinoid receptor antagonist RN 1734 yielded the highest potency in reducing the viability of human colon adenocarcinoma Colo-205 cells compared to the other cannabinoid receptor antagonists being tested. However, this observation warrants further investigations since their work did not involve the assessment of TRPV4 expression levels in Colo-205 cells. Using gastric cancer cells, recent work by Xie and his co-workers28<\/sup> discovered a co-localisation of calcium-sensing receptor (CaSR) and TRPV4 and that activation of CaSR promotes Ca2+<\/sup> entry via TRPV4 channel. They also demonstrated a functional coupling of CaSR and TRPV4 which is implicated in the proliferation of gastric cancer cells. This is evidenced by attenuation of CaSR-induced proliferation of gastric cancer cells in the presence of TRPV4 inhibitor RN 1734.28<\/sup> Taken together, current lines of evidence suggest that TRPV4 appears to play some roles in the proliferation of cancer cells; however, this role may be cancer cell type specific.<\/p>\n

TRPV4 and Apoptosis<\/strong><\/p>\n

The role of TRPV4 in apoptosis has been reported in some study models, for example, the involvement of TRPV4 in apoptosis of mouse retinal ganglion cells (29) and mouse pancreatic beta cells.30<\/sup> Recent studies have begun to suggest a role for TRPV4 in inducing cell death, particularly in breast cancer cells which overexpress TRPV4. Peters et al<\/em>\u00a026<\/sup> demonstrated that there was a reduction in the viability of two basal breast cancer cell lines, MDA-MB-468 and HCC1569 as a result of pharmacological activation of TRPV4. These two cell lines showed an overexpression of TRPV4. Results from their studies have provided new insights into the role of TRPV4 in inducing breast cancer cell death via two distinct pathways: apoptosis and oncosis.26<\/sup> Apoptosis was related to PARP-1 cleavage while oncosis was corresponded to a rapid decline in intracellular ATP levels.26<\/sup> The researchers also observed that TRPV4 activation leads to decreased tumour growth in vivo,<\/em>26<\/sup> suggesting that targeting TRPV4 may be relevant for breast cancers that overexpress this specific Ca2+<\/sup> channel.<\/p>\n

TRPV4 and Angiogenesis<\/strong><\/p>\n

Angiogenesis is the formation of new blood vessels which is important for cancer cells in order to receive sufficient oxygen and nutrients and also for waste products removal.31<\/sup> The early evidence to link TRPV4 with breast cancer in the context of angiogenesis is demonstrated by Fiorio Pla et al<\/em>32<\/sup> who discovered the importance of TRPV4 in mediating arachidonic acid (AA)-induced migration of breast tumour-derived endothelial cells (BTEC), which is one of the key events in tumour angiogenesis. The authors found that endogenous expression of TRPV4 was significantly higher in BTEC than the corresponding \u2018normal\u2019 endothelial cells (HMVEC). They also confirmed that TRPV4 is functional in both cell types since stimulation with AA and the TRPV4 activator 4\u03b1-phorbol 12,13-didecanoate (4\u03b1-PDD) produced increases in [Ca2+<\/sup>]CYT<\/sub>, which is more pronounced in BTEC compared to HMVEC cells.32<\/sup> Further functional studies using the widely used non-specific TRPV4 antagonist ruthenium red and short hairpin RNA against TRPV4 completely abolished AA-induced BTEC migration, indicating that TRPV4 is involved in the migration of BTEC. The pro-migratory effect of TRPV4 upon stimulation with 4\u03b1-PDD or AA on BTEC further illustrates a direct association between TRPV4 and AA-mediated cell migration.32<\/sup><\/p>\n

Subsequent studies by Adapala and co-researchers33<\/sup> have provided further evidence on the role of TRPV4 in regulating TEC mechanosensitivity, tumour angiogenesis and tumour vessel maturation. The team uncovered that TEC express lower levels of TRPV4 than normal endothelial cells. The observed downregulation of TRPV4 has been associated with altered mechanosensitivity and abnormal tumour angiogenesis in TEC and also enhanced tumour growth in TRPV4-deficient (TRPV4 KO) mice.33<\/sup> All of the aforementioned effects are reversed upon stimulation with TRPV4 pharmacological activator or restoring TRPV4 expression,33<\/sup> reiterating the role of TRPV4 in tumour angiogenesis. They also demonstrated that TRPV4 activation combined with a chemotherapy drug cisplatin, significantly suppresses tumour growth in vivo<\/em> by normalising tumour vasculature which improves the effectiveness of cisplatin therapy.33<\/sup> Indeed, findings by Adapala et al<\/em>\u00a033<\/sup> strongly support the rationale for targeting TRPV4 particularly for anti-angiogenic and vascular normalisation therapies.<\/p>\n

Further work by Thoppil et al<\/em>34<\/sup> have elucidated the molecular mechanism by which TRPV4 may regulate tumour angiogenesis. Their investigations were focused on the Rho\/Rho kinase pathway which is essential for tumour growth and progression.35<\/sup> The researchers identified that, compared to wild type endothelial cells, the loss of TRPV4 in TRPV4 null endothelial cells (TRPV4KO EC) is associated with enhanced proliferation, migration and abnormal angiogenesis.34<\/sup> Furthermore, their analysis of Rho activity revealed that treatment with the Rho\/Rho kinase pathway inhibitor Y-27632 is able to normalise abnormal\u00a0 mechanosensitivity and angiogenesis displayed by TRPV4KO EC, suggesting that TRPV4 regulates tumour angiogenesis by modulating endothelial cells mechanosensitivity through the Rho\/Rho kinase pathway.34<\/sup> Collectively, based on the evidence outlined above, TRPV4 is indeed an attractive drug target for therapeutic intervention in the context of angiogenesis.<\/p>\n

TRPV4 and Metastasis<\/strong><\/p>\n

In addition to the reported role of TRPV4 in tumour angiogenesis,24,32-34<\/sup> recent studies by Lee and co-workers 25<\/sup> highlighted a novel role of TRPV4 in breast cancer metastasis. Using phosphoproteomics analysis, the researchers detected a significant upregulation of TRPV4 in breast cancer metastasis model cell lines, where its upregulation has been associated with the acquisition of the extravasation trait. Their assessment of TRPV4 expression in human clinical samples using public databases revealed that TRPV4 expression is also enriched in basal subtype of breast cancer and is associated with a more aggressive phenotype and poor survival. Both TRPV4 siRNA-mediated knockdown and pharmacological inhibition of TRPV4 lead to suppression of migration and invasion of the TRPV4-high 4T07 breast cancer cell line, further confirming the involvement of TRPV4 in metastatic processes.25<\/sup> Further functional experiments unravelled that TRPV4 is vital for regulating cancer cell stiffness and cell cortex dynamics required for cancer cell metastasis. 25<\/sup> Subsequent studies by the same research group attempted to establish the precise mechanism for the pro-migratory and pro-metastatic effects of TRPV4 in breast cancer.36<\/sup> They reported that TRPV4 mediates breast cancer metastasis by regulating cancer cell softness via Ca2+<\/sup>-dependent AKT-E-cadherin signalling axis as well as the expression of extracellular proteins involved in cytoskeleton and extracellular matrix remodelling.36<\/sup><\/p>\n

The mechanosensitive ion channel TRPV4 has also been documented to be implicated in the migration of human hepatoblastoma HepG2 cells,37<\/sup> which is one the multiple steps involved in cancer metastasis.38<\/sup> A study by Waning and colleagues37<\/sup> showed that application of a TRPV4 agonist 4\u03b1-PDD results in an increase in lamellipodial dynamics in HepG2 cells pre-treated with hepatocyte growth factor, indicating that functionally expressed TRPV4 channel does play a role in mediating Ca2+<\/sup> influx required for the migration of HepG2 cells.<\/p>\n

Apart from reports on TRPV4\u2019s function in breast cancer metastasis,25,36<\/sup> TRPV4 has also been recently shown to be involved in gastric cancer metastasis.28<\/sup> The researchers observed that CaSR activation induces human gastric cancer growth and metastasis, which is achieved by TRPV4-evoked increases in Ca2+<\/sup> influx which in turn, activates AKT\/\u03b2-catenin signalling pathway.28<\/sup> Altogether, although studies assessing the potential role of TRPV4 in cancer metastasis are still in their infancy, current findings should prompt further research on the likelihood of TRPV4 as a drug candidate for cancer therapy, especially in the case of metastatic cancers.<\/p>\n

Conclusions<\/strong><\/p>\n

TRPV4 ion channel is Ca2+<\/sup>-permeable and it is one of the TRPV members which is implicated in cancer progression. This review has provided compelling evidence for the emerging roles of TRPV4 in several aspects of cancer progression, with a focus on the cancer hallmarks. As discussed above, it is clear that there is involvement of TRPV4 in cancer progression particularly in the context of cell proliferation, apoptosis, angiogenesis and metastasis. Table 1 summarises all studies assessing TRPV4 and its potential role in various cancer types. Given the essential roles of TRPV4 in cancer progression and aberrant expression of TRPV4 in some cancer tissues compared to their normal counterparts, it is very likely that TRPV4 will emerge as a potential drug target with therapeutic benefits in various cancer types such as breast cancer.<\/p>\n

Table 1: Studies on TRPV4 and cancers.<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Cancer type<\/strong><\/td>\nChanges in TRPV4 expression levels<\/strong><\/td>\nPossible role of TRPV4 and mechanism proposed<\/strong><\/td>\n<\/tr>\n
Breast cancer<\/td>\nUpregulated in basal breast cancers (25, 26), in BTEC (32), in breast cancer metastasis model cell lines (25) and in the metastatic lesions of breast cancer clinical samples (36)<\/td>\nPharmacological activation of TRPV4 promotes cell death via oncosis and apoptosis in breast cancer cells overexpressing TRPV4 and also suppresses tumour cell growth in vivo<\/em> (26)<\/td>\n<\/tr>\n
Inhibition of TRPV4 in breast cancer cell lines with endogenous expression of TRPV4 has no effect on cell proliferation (25, 26)<\/td>\n<\/tr>\n
TRPV4 is important for the migration of breast tumour-derived endothelial cells (32)<\/td>\n<\/tr>\n
TRPV4 is required for breast cancer metastasis by regulating cancer cell stiffness via Ca2+<\/sup>-dependent activation of AKT and downregulation of\u00a0 E-cadherin cell cortex protein (25, 36)<\/td>\n<\/tr>\n
Tumour endothelial cells (TEC)<\/td>\nDownregulated in TEC<\/td>\nTRPV4 regulates tumour angiogenesis by inhibiting TEC proliferation via modulation of ERK pathway (24)<\/td>\n<\/tr>\n
TRPV4 is a critical regulator of TEC mechanosensitivity, tumour angiogenesis and tumour vessel maturation by modulating Rho signalling pathway (33, 34)<\/td>\n<\/tr>\n
Skin cancer<\/td>\nDownregulated from a healthy to a skin cancer phenotype<\/td>\nThe loss of TRPV4 expression in skin cancer implicates that TRPV4 may represent an early biomarker of skin carcinogenesis (39)<\/td>\n<\/tr>\n
Colorectal cancer<\/td>\nUpregulated (TRPV4 expression was obtained from the ICGC data)<\/td>\nNo mechanism assessed (40)<\/td>\n<\/tr>\n
Downregulated in patient tissue samples<\/td>\nNo mechanism assessed; however, the authors postulated that epigenetic influence may be involved in the downregulation of TRPV4 in colorectal cancer (41)<\/td>\n<\/tr>\n
No assessment of TRPV4 expression in human colon adenocarcinoma Colo-205 cells<\/td>\nTRPV4 may be important for colorectal cancer cell proliferation since co-incubation of FAAH inhibitor PF-3845 with the TRPV4 antagonist RN 1734 remarkably decreased the viability of Colo-205 cells (27)<\/td>\n<\/tr>\n
Liver cancer<\/td>\nDownregulated (TRPV4 expression was obtained from the ICGC data)<\/td>\nNo mechanism assessed (40)<\/td>\n<\/tr>\n
Functionally expressed in human hepatoblastoma HepG2 cells<\/td>\nTRPV4 provides a Ca2+<\/sup> entry pathway in HepG2 cells and is implicated in the migration of this cell line (37, 42)<\/td>\n<\/tr>\n
Gastric cancer<\/td>\nExpressed in both normal gastric and GC cells<\/td>\nTRPV4 provides a Ca2+<\/sup> entry route upon activation of CaSR in GC cells which in turn stimulates proliferation and migration of GC cells through Ca2+<\/sup>\/AKT\/\u03b2-catenin signalling pathway (28)<\/td>\n<\/tr>\n
Cervical cancer<\/td>\nUpregulated (TRPV4 expression was obtained from the ICGC data)<\/td>\nNo mechanism assessed (40)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

BTEC = breast tumour-derived endothelial cells; TEC = tumour endothelial cells; ICGC = International Cancer Genome Consortium; FAAH = fatty acid amide hydrolase; CaSR = calcium-sensing receptor; GC = gastric cancer.<\/p>\n

Acknowledgements<\/strong><\/p>\n

The authors would like to thank Prof. Dr. Srijit Das (The National University of Malaysia) for his assistance in proofreading this manuscript. This work was supported by the Fundamental Research Grant Scheme (RR 202) from the Ministry of Higher Education Malaysia.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

There is no\u00a0conflict of interest<\/p>\n

Funding Source<\/strong><\/p>\n

This work was funded by the Fundamental Research Grant Scheme (RR 202) from the Ministry of Higher Education Malaysia.<\/p>\n

References<\/strong><\/p>\n

    \n
  1. Clapham D. E., Runnels L. W., Strubing C. The TRP ion channel family. Nat Rev Neurosci.<\/em> 2001;2(6):387-96.
    \nCrossRef<\/a><\/li>\n
  2. Montell C. The TRP superfamily of cation channels. Sci STKE.<\/em> 2005;2005(272):3.
    \n    CrossRef<\/a><\/li>\n
  3. Strotmann R., Harteneck C., Nunnenmacher K., Schultz G., Plant T. D.\u00a0 OTRPC4 a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol.<\/em> 2000;2:695-702.
    \n    CrossRef<\/a><\/li>\n
  4. Chung M. K., Lee H., Caterina M. J.\u00a0 Warm temperatures activate TRPV4 in mouse 308 keratinocytes. J Biol Chem<\/em>. 2003;278(34):32037-46.
    \n    CrossRef<\/a><\/li>\n
  5. Liedtke W., Tobin D. M., Bargmann C. I., Friedman J. M.\u00a0 Mammalian TRPV4 (VR-OAC) directs behavioral responses to osmotic and mechanical stimuli in Caenorhabditis elegans. Proc Natl Acad Sci U S A<\/em>. 2003;100(2):14531-6.
    \n    CrossRef<\/a><\/li>\n
  6. Watanabe H., Davis J. B., Smart D., Jerman J. C., Smith G. D., Hayes P., et al. Activation of TRPV4 channels (hVRL-2\/mTRP12) by phorbol derivatives. J Biol Chem<\/em>. 2002;277(16):13569-77.
    \n    CrossRef<\/a><\/li>\n
  7. Watanabe H., Vriens J., Prenen J., Droogmans G., Voets T., Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature.<\/em> 2003;424:434-8.
    \n    CrossRef<\/a><\/li>\n
  8. Watanabe H., Vriens J., Suh S. H., Benham C. D., Droogmans G., Nilius B. Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cells. J Biol Chem<\/em>. 2002;277(49):47044-51.
    \n    CrossRef<\/a><\/li>\n
  9. Bolanz K. A., Hediger M. A., Landowski C. P. The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther.<\/em> 2008;7(2):271-9.
    \n    CrossRef<\/a><\/li>\n
  10. Peters A. A., Simpson P. T., Bassett J. J., Lee J. M.,\u00a0 Silva L. D., Reid L. E., et al. Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther.<\/em> 2012;11:2158-68.
    \n    CrossRef<\/a><\/li>\n
  11. Shi Y., Ding X., He Z. H., Zhou K. C., Wang Q., Wang Y. Z.\u00a0 Critical role of TRPC6 channels in G2 phase transition and the development of human oesophageal cancer. Gut.<\/em> 2009;58(11):1443-50.
    \n    CrossRef<\/a><\/li>\n
  12. Yang S. L., Cao Q., Zhou K. C., Feng Y. J., Wang Y. Z.\u00a0 Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. Oncogene.<\/em> 2009;28(10):1320-8.
    \n    CrossRef<\/a><\/li>\n
  13. Yang Z. H., Wang X. H., Wang H. P., Hu L. Q. Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl<\/em>. 200;11(2):157-65.
    \n    CrossRef<\/a><\/li>\n
  14. Zhang L., Barritt G. J.\u00a0 Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res.<\/em> 2004;64:8365-73.
    \n    CrossRef<\/a><\/li>\n
  15. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell.<\/em> 2000;100(1):57-70.
    \n    CrossRef<\/a><\/li>\n
  16. Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell.<\/em> 2011;144:646-74.
    \n    CrossRef<\/a><\/li>\n
  17. Santoni G., Farfariello V., Amantini C. TRPV channels in tumor growth and progression. Adv Exp Med Biol.<\/em> 2011;704:947-67.
    \n    CrossRef<\/a><\/li>\n
  18. Dhennin-Duthille I., Gautier M., Faouzi M., Guilbert A., Brevet M., Vaudry D., et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues correlation with pathological parameters. Cell Physiol Biochem.<\/em> 2011;28(5):813-22.
    \n    CrossRef<\/a><\/li>\n
  19. Fixemer T., Wissenbach U., Flockerzi V., Bonkhoff H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer a novel prognostic marker for tumor progression. Oncogene.<\/em> 2003;22(49):7858-61.
    \n    CrossRef<\/a><\/li>\n
  20. Lehen’kyi V., Raphael M., Prevarskaya N. The role of the TRPV6 channel in cancer. J Physiol<\/em>. 2012;590(6):1369-76.
    \n    CrossRef<\/a><\/li>\n
  21. Zhuang L., Peng J. B., Tou L., Takanaga H., Adam R. M., Hediger M. A., et al. Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Invest.<\/em> 2002;82:1755-64.
    \n    CrossRef<\/a><\/li>\n
  22. Hatano N., Suzuki H., Itoh Y., Muraki K. TRPV4 partially participates in proliferation of human brain capillary endothelial cells. Life Sci.<\/em> 2013;92(4-5):317-24.
    \n    CrossRef<\/a><\/li>\n
  23. Ueda T., Shikano M., Kamiya T., Joh T., Ugawa S. The TRPV4 channel is a novel regulator of intracellular Ca2+ in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol<\/em>. 2011;301:138-47.
    \n    CrossRef<\/a><\/li>\n
  24. Thoppil R. J., Adapala R. K., Cappelli H. C., Kondeti V., Dudley A. C., Gary Meszaros J., et al. TRPV4 channel activation selectively inhibits tumor endothelial cell proliferation. Sci Rep<\/em>. 2015;5:14257.
    \n    CrossRef<\/a><\/li>\n
  25. Lee W. H., Choong L. Y., Mon N. N., Lu S., Lin Q., Pang B., et al. TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex. Sci Rep.<\/em> 2016;6:27903.
    \n    CrossRef<\/a><\/li>\n
  26. Peters A. A., Jamaludin S. Y. N., Yapa K. T. D. S., Chalmers S., Wiegmans A. P., Lim H. F., et al. Oncosis and apoptosis induction by activation of an overexpressed ion channel in breast cancer cells. Oncogene<\/em>. 2017.
    \n    CrossRef<\/a><\/li>\n
  27. Wasilewski A., Krajewska U., Owczarek K., Lewandowska U., Fichna J. Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line an in vitro study. Acta Biochim Pol.<\/em> 2017;64(3):519-25.
    \n    CrossRef<\/a><\/li>\n
  28. Xie R., Xu J., Xiao Y. F., Wu J., Wan H., Tang B., et al. Calcium promotes human gastric cancer via a novel coupling of calcium-sensing receptor and TRPV4 channel. Cancer Res.<\/em> 2017.
    \n    CrossRef<\/a><\/li>\n
  29. Ryskamp D. A., Witkovsky P., Barabas P., Huang W., Koehler C., Akimov N. P., et al. The polymodal ion channel transient receptor potential vanilloid 4 modulates calcium flux, spiking rate, and apoptosis of mouse retinal ganglion cells. J Neurosci<\/em>. 201;31(19):7089-101.
    \n    CrossRef<\/a><\/li>\n
  30. Casas S., Novials A., Reimann F., Gomis R., Gribble F. M. Calcium elevation in mouse pancreatic beta cells evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion channel TRPV4. Diabetologia. 2008;51(12):2252-62.
    \n    CrossRef<\/a><\/li>\n
  31. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag<\/em>. 2006;2(3):213-9.
    \n    CrossRef<\/a><\/li>\n
  32. Pla A. F., Ong H. L., Cheng K. T., Brossa A., Bussolati B., Lockwich T., et al. TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling. Oncogene.<\/em> 2012;31(2):200-12.
    \n    CrossRef<\/a><\/li>\n
  33. Adapala R. K., Thoppil R. J., Ghosh K., Cappelli H. C., Dudley A. C., Paruchuri S., et al. Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene.<\/em> 2016;35(3):314-22.
    \n    CrossRef<\/a><\/li>\n
  34. Thoppil RJ, Cappelli HC, Adapala RK, Kanugula AK, Paruchuri S, Thodeti CK. TRPV4 channels regulate tumor angiogenesis via modulation of Rho\/Rho kinase pathway. Oncotarget. 2016 May 03;7(18):25849-61.
    \n    CrossRef<\/a><\/li>\n
  35. Rath N., Olson M. F. Rho-associated kinases in tumorigenesis re-considering ROCK inhibition for cancer therapy. EMBO Rep.<\/em> 2012;13(10):900-8.
    \n    CrossRef<\/a><\/li>\n
  36. Lee W. H., Choong L. Y., Jin T. H., Mon N. N., Chong S., Liew C. S., et al. TRPV4 plays a role in breast cancer cell migration via Ca2+-dependent activation of AKT and downregulation of E-cadherin cell cortex protein. Oncogenesis.<\/em> 2017;22;6(5):e338.
    \n    CrossRef<\/a><\/li>\n
  37. Waning J., Vriens J., Owsianik G., Stuwe L., Mally S., Fabian A., et al. A novel function of capsaicin-sensitive TRPV1 channels: involvement in cell migration. Cell Calcium.<\/em> 2007;42(1):17-25.
    \n    CrossRef<\/a><\/li>\n
  38. Sahai E. Illuminating the metastatic process. Nat Rev Cancer<\/em>. 2007;7(10):737-49.
    \n    CrossRef<\/a><\/li>\n
  39. Fusi C., Materazzi S., Minocci D., Maio V., Oranges T., Massi D., et al. Transient receptor potential vanilloid 4 (TRPV4) is downregulated in keratinocytes in human non-melanoma skin cancer. J Invest Dermatol.<\/em> 2014;134(9):2408-17.
    \n    CrossRef<\/a><\/li>\n
  40. Park Y. R., Chun J. N., So I., Kim H. J., Baek S., Jeon J. H., et al. Data-driven Analysis of TRP Channels in Cancer: Linking Variation in Gene Expression to Clinical Significance. Cancer Genomics Proteomic<\/em>s. 2016 01-02;13(1):83-90.<\/li>\n
  41. Sozucan Y., Kalender M. E., Sari I., Suner A., Oztuzcu S., Arman K., et al. TRP genes family expression in colorectal cancer. Exp Oncol<\/em>. 2015;37(3):208-12.<\/li>\n
  42. Vriens J., Janssens A., Prenen J., Nilius B., Wondergem R. TRPV channels and modulation by hepatocyte growth factor\/scatter factor in human hepatoblastoma (HepG2) cells. Cell Calcium.<\/em> 2004;36(1):19-28.
    \n    CrossRef<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Introduction The transient receptor potential (TRP) ion channel family constitutes […]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53],"tags":[],"class_list":["post-18117","post","type-post","status-publish","format-standard","hentry","category-vol10no4"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/18117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=18117"}],"version-history":[{"count":13,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/18117\/revisions"}],"predecessor-version":[{"id":24010,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/18117\/revisions\/24010"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=18117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=18117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=18117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}